NO321329B1 - Fremgangsmate til a fastsette kjemoterapi for pasienter som er HIV positive, basert pa fenotypisk legemiddelfolsomhet hos pasientens HIV-stammer - Google Patents
Fremgangsmate til a fastsette kjemoterapi for pasienter som er HIV positive, basert pa fenotypisk legemiddelfolsomhet hos pasientens HIV-stammer Download PDFInfo
- Publication number
- NO321329B1 NO321329B1 NO19983300A NO983300A NO321329B1 NO 321329 B1 NO321329 B1 NO 321329B1 NO 19983300 A NO19983300 A NO 19983300A NO 983300 A NO983300 A NO 983300A NO 321329 B1 NO321329 B1 NO 321329B1
- Authority
- NO
- Norway
- Prior art keywords
- hiv
- chimeric
- inhibitors
- patient
- sensitivity
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 77
- 230000035945 sensitivity Effects 0.000 title claims abstract description 40
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 27
- 229940079593 drug Drugs 0.000 title claims description 60
- 239000003814 drug Substances 0.000 title claims description 60
- 239000003112 inhibitor Substances 0.000 claims abstract description 80
- 241000700605 Viruses Species 0.000 claims abstract description 46
- 108700004029 pol Genes Proteins 0.000 claims abstract description 28
- 101150088264 pol gene Proteins 0.000 claims abstract description 28
- 102000004190 Enzymes Human genes 0.000 claims abstract description 17
- 108090000790 Enzymes Proteins 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 238000012258 culturing Methods 0.000 claims abstract description 5
- 230000000007 visual effect Effects 0.000 claims abstract description 3
- 102100034343 Integrase Human genes 0.000 claims description 65
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 60
- 210000004027 cell Anatomy 0.000 claims description 38
- 108091005804 Peptidases Proteins 0.000 claims description 24
- 239000013612 plasmid Substances 0.000 claims description 19
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 18
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 18
- 238000001890 transfection Methods 0.000 claims description 18
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 17
- 239000004365 Protease Substances 0.000 claims description 14
- 239000012620 biological material Substances 0.000 claims description 13
- 239000002777 nucleoside Substances 0.000 claims description 13
- 230000002441 reversible effect Effects 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 12
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 12
- 230000008901 benefit Effects 0.000 claims description 11
- 238000010276 construction Methods 0.000 claims description 11
- 101150104269 RT gene Proteins 0.000 claims description 9
- 229940124524 integrase inhibitor Drugs 0.000 claims description 9
- 239000002850 integrase inhibitor Substances 0.000 claims description 9
- 108020000999 Viral RNA Proteins 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 7
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 7
- 238000004520 electroporation Methods 0.000 claims description 6
- SWUARLUWKZWEBQ-VQHVLOKHSA-N phenethyl caffeate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-VQHVLOKHSA-N 0.000 claims description 6
- SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 claims description 6
- 108010061833 Integrases Proteins 0.000 claims description 5
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 229960001936 indinavir Drugs 0.000 claims description 5
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 5
- 238000010839 reverse transcription Methods 0.000 claims description 5
- 229960000311 ritonavir Drugs 0.000 claims description 5
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 5
- ZNFFMCYSMBXZQU-NSHDSACASA-N 5-chloro-8-methyl-7-(3-methyl-but-2-enyl)-6,7,8,9-tetrahydro-2h-2,7,9a-triaza-benzo[cd]azulene-1-thione Chemical compound C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=C(Cl)C1=C32 ZNFFMCYSMBXZQU-NSHDSACASA-N 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 229950006243 loviride Drugs 0.000 claims description 4
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960001852 saquinavir Drugs 0.000 claims description 4
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 4
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 230000001788 irregular Effects 0.000 claims description 3
- 229960000689 nevirapine Drugs 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 229950011282 tivirapine Drugs 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000005013 brain tissue Anatomy 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 238000000423 cell based assay Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 27
- PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 abstract description 4
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 93
- 238000003752 polymerase chain reaction Methods 0.000 description 30
- 230000035772 mutation Effects 0.000 description 16
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 16
- 229960002555 zidovudine Drugs 0.000 description 15
- 230000008859 change Effects 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 230000006798 recombination Effects 0.000 description 12
- 238000005215 recombination Methods 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000009104 chemotherapy regimen Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 8
- 238000002955 isolation Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000001566 pro-viral effect Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 4
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 101710203526 Integrase Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 3
- 230000000798 anti-retroviral effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- -1 ddl Chemical compound 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229940124821 NNRTIs Drugs 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960002656 didanosine Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940127073 nucleoside analogue Drugs 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229940099797 HIV integrase inhibitor Drugs 0.000 description 1
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 102220500387 Neutral and basic amino acid transport protein rBAT_M41Y_mutation Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003084 hiv integrase inhibitor Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000012247 phenotypical assay Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- WTTIBCHOELPGFK-LBPRGKRZSA-N r82150 Chemical compound C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=CC1=C32 WTTIBCHOELPGFK-LBPRGKRZSA-N 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940063627 rescriptor Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229940064914 retrovir Drugs 0.000 description 1
- 102220011161 rs727504317 Human genes 0.000 description 1
- 102200069353 rs8103142 Human genes 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940098802 viramune Drugs 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96200175 | 1996-01-26 | ||
| PCT/IB1997/000071 WO1997027480A1 (en) | 1996-01-26 | 1997-01-24 | Method of managing the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO983300D0 NO983300D0 (no) | 1998-07-16 |
| NO983300L NO983300L (no) | 1998-09-25 |
| NO321329B1 true NO321329B1 (no) | 2006-04-24 |
Family
ID=8223611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19983300A NO321329B1 (no) | 1996-01-26 | 1998-07-16 | Fremgangsmate til a fastsette kjemoterapi for pasienter som er HIV positive, basert pa fenotypisk legemiddelfolsomhet hos pasientens HIV-stammer |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US6221578B1 (de) |
| EP (1) | EP0877937B1 (de) |
| KR (1) | KR100495690B1 (de) |
| CN (2) | CN1209875A (de) |
| AT (1) | ATE217971T1 (de) |
| AU (1) | AU717755B2 (de) |
| BG (1) | BG102710A (de) |
| BR (1) | BR9707204A (de) |
| CZ (1) | CZ292899B6 (de) |
| DE (1) | DE69712731T2 (de) |
| ES (1) | ES2177922T3 (de) |
| HU (1) | HU226203B1 (de) |
| IL (1) | IL125442A (de) |
| IS (1) | IS4799A (de) |
| NO (1) | NO321329B1 (de) |
| NZ (1) | NZ325912A (de) |
| PL (1) | PL186473B1 (de) |
| SK (1) | SK283878B6 (de) |
| TR (1) | TR199801443T2 (de) |
| WO (1) | WO1997027480A1 (de) |
| ZA (1) | ZA97669B (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE172717T1 (de) | 1992-08-25 | 1998-11-15 | Searle & Co | Hydroxyethylaminosulfonamide verwendbar als inhibitoren retroviraler proteasen |
| US20030220276A1 (en) * | 1995-05-16 | 2003-11-27 | Opendra Narayan | HIV vaccine and method of use |
| US6242187B1 (en) | 1996-01-29 | 2001-06-05 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| US20070010471A1 (en) * | 1997-05-02 | 2007-01-11 | Opendra Narayan | HIV DNA vaccine |
| CA2298102A1 (en) * | 1997-07-30 | 1999-02-11 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| CA2329140A1 (en) * | 1998-05-26 | 1999-12-02 | Virologic, Inc. | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy |
| NZ516259A (en) | 1999-05-28 | 2004-02-27 | Virco N | New mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance |
| US6800437B1 (en) | 1999-08-06 | 2004-10-05 | Tibotec Bvba | Method of monitoring a biological system by labeling with an apo metal binding protein |
| EP1109019A1 (de) * | 1999-12-15 | 2001-06-20 | BioStrands S.r.l. | Verfahren zur Ermittlung der Empfindlichkeit von HIV-Varianten gegen Hemmstoffe der HIV-Protease |
| AU2001233513A1 (en) * | 2000-02-04 | 2001-08-14 | K.U. Leuven Research And Development | Hiv-1 resistance assay |
| GB0009374D0 (en) * | 2000-04-14 | 2000-05-31 | Glaxo Group Ltd | Phenotyping assay and reagents therefor |
| WO2001079540A2 (en) | 2000-04-18 | 2001-10-25 | Virco Bvba | Methods for measuring drug resistance |
| US6800463B1 (en) * | 2000-04-20 | 2004-10-05 | Virco Bvba | Method for mutation detection in HIV-1 using pol sequencing |
| AU2001256318B8 (en) * | 2000-04-20 | 2007-03-22 | Virco Bvba | Method for mutation detection in HIV using pol sequencing |
| US6582901B2 (en) * | 2000-04-26 | 2003-06-24 | Bruce K. Patterson | Cell specific anti-viral drug susceptibility test using tagged permissive target cells |
| US7058616B1 (en) | 2000-06-08 | 2006-06-06 | Virco Bvba | Method and system for predicting resistance of a disease to a therapeutic agent using a neural network |
| EP1292712A4 (de) * | 2000-06-12 | 2005-04-20 | Virologic Inc | Vorrichtungen und methoden zur ueberwachung von antiretroviraler therapie und zur hinführung zu therapeutischen entscheidungen bei der behandlung von hiv/aids |
| US6582920B2 (en) * | 2000-09-01 | 2003-06-24 | Gen-Probe Incorporated | Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations |
| AU2002226316B2 (en) | 2000-10-20 | 2008-06-26 | Virco Bvba | Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance |
| ES2321809T3 (es) * | 2000-10-20 | 2009-06-12 | Virco Bvba | Establecimiento de valores e corte biologicos para predecir la resistencia a la terapia. |
| US6958211B2 (en) * | 2001-08-08 | 2005-10-25 | Tibotech Bvba | Methods of assessing HIV integrase inhibitor therapy |
| EP1283272B1 (de) * | 2001-08-08 | 2013-11-13 | Janssen R&D Ireland | Verfahren und Mittel zur Bewertung einer gegen das HIV Hüllprotein (env) gerichteten Inhibitortherapie |
| US7320878B2 (en) | 2001-11-08 | 2008-01-22 | Tibotec Pharmaceuticals, Ltd. | Protease assay for therapeutic drug monitoring |
| EP1522039B1 (de) | 2002-07-01 | 2008-06-04 | Tibotec Pharmaceuticals Ltd. | Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase |
| AU2003254500B2 (en) | 2002-07-01 | 2009-11-19 | Tibotec Pharmaceuticals Ltd. | Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance |
| AU2005218183B2 (en) * | 2004-03-02 | 2012-06-07 | Virco Bvba | Estimation of clinical cut-offs |
| US8673551B2 (en) | 2005-12-07 | 2014-03-18 | Speedx Pty Ltd. | Methods, plasmid vectors and primers for assessing HIV viral fitness |
| EP2010680A2 (de) * | 2006-04-14 | 2009-01-07 | Tibotec Pharmaceuticals Ltd. | Verfahren und mittel zur beurteilung von hiv-gag-/proteasehemmer-therapie |
| AU2008257703A1 (en) | 2007-05-25 | 2008-12-04 | Tibotec Pharmaceuticals | New mutational profile in HIV-1 Gag cleavage site correlated with phenotypic drug resistance |
| WO2010040756A1 (en) * | 2008-10-06 | 2010-04-15 | Virco Bvba | Method for determining drug resistance mutations in any of the non-structural protein regions ns3 to ns5b of hepatitis c virus (hcv) for genotypes 1 to 6 |
| AU2010247444A1 (en) * | 2009-05-12 | 2011-11-24 | Virco Bvba | HIV-1-C resistance monitoring |
| CN107085093B (zh) * | 2017-03-24 | 2019-06-21 | 西藏诺迪康药业股份有限公司 | 重组人白细胞介素1受体拮抗剂滴眼液生物学活性的检测方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3875396A (en) | 1973-11-12 | 1975-04-01 | Illuminite Corp | Illuminated clipboard |
| US4675147A (en) * | 1983-04-06 | 1987-06-23 | Westinghouse Electic Corp. | Generating an integrated graphic display of the safety status of a complex process plant |
| US5716826A (en) * | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| ES2166748T3 (es) | 1989-05-25 | 2002-05-01 | Novartis Ag | Represor multivalente de la funcion genica. |
| US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
| JPH05148202A (ja) * | 1991-04-10 | 1993-06-15 | Tsumura & Co | 新規な化合物およびその医薬としての用途 |
| WO1993023574A1 (en) | 1992-05-14 | 1993-11-25 | Kozal Michael J | Polymerase chain reaction assays for monitoring antiviral therapy |
| US5733720A (en) | 1992-06-18 | 1998-03-31 | Washington University | Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor |
| AU687353B2 (en) | 1992-07-06 | 1998-02-26 | President And Fellows Of Harvard College | Methods and diagnostic kits for determining toxicity utilizing bacterial stress promoters fused to reporter genes |
| US5344846A (en) | 1992-12-30 | 1994-09-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells |
| US5591579A (en) | 1993-12-21 | 1997-01-07 | Washington University | Indicator cell line for detecting RNA viruses and method therefor |
| US6063562A (en) | 1994-09-16 | 2000-05-16 | Sepracor, Inc. | In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst |
| US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
| EP0914607A2 (de) | 1995-09-15 | 1999-05-12 | Samir Chachoua | Verfahren zur erkennung und therapeutische verwendung von krankheitsassoziierten organismen, elementen und kräften |
| US5885806A (en) * | 1995-11-28 | 1999-03-23 | The Johns Hopkins University School Of Medicine | Methods to prepare conditionally replicating viral vectors |
| US5837464A (en) | 1996-01-29 | 1998-11-17 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| NZ331376A (en) | 1996-01-29 | 2000-03-27 | Virologic Inc | Methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| US5945276A (en) | 1996-04-10 | 1999-08-31 | Signal Pharmaceuticals, Inc. | Reporter cell line system for detecting cytomegalovirus and identifying modulators of viral gene expression |
| US5939253A (en) | 1996-04-26 | 1999-08-17 | Diagnostic Hybrids, Inc. | Compositions and methods for detecting viral infection |
| WO1998045704A2 (en) | 1997-04-07 | 1998-10-15 | Bioimage A/S | A method for extracting quantitative information relating to an influence on a cellular response |
| WO1998046796A1 (en) | 1997-04-11 | 1998-10-22 | The Regents Of The University Of California | A method of screening nucleotide sequences to identify disruptors or effectors of biological processes or pathways |
| AU8160298A (en) | 1997-06-23 | 1999-01-04 | Emory University | Human immunodeficiency viruses causing aids in a nonhuman primate |
| US5976813A (en) | 1997-12-12 | 1999-11-02 | Abbott Laboratories | Continuous format high throughput screening |
-
1997
- 1997-01-24 CN CN97191904A patent/CN1209875A/zh active Pending
- 1997-01-24 WO PCT/IB1997/000071 patent/WO1997027480A1/en not_active Application Discontinuation
- 1997-01-24 AT AT97900712T patent/ATE217971T1/de active
- 1997-01-24 BR BR9707204-4A patent/BR9707204A/pt not_active Application Discontinuation
- 1997-01-24 CN CNA2006101685069A patent/CN1991365A/zh active Pending
- 1997-01-24 DE DE69712731T patent/DE69712731T2/de not_active Expired - Lifetime
- 1997-01-24 IL IL12544297A patent/IL125442A/en not_active IP Right Cessation
- 1997-01-24 US US09/117,217 patent/US6221578B1/en not_active Expired - Lifetime
- 1997-01-24 EP EP97900712A patent/EP0877937B1/de not_active Expired - Lifetime
- 1997-01-24 ES ES97900712T patent/ES2177922T3/es not_active Expired - Lifetime
- 1997-01-24 SK SK1002-98A patent/SK283878B6/sk not_active IP Right Cessation
- 1997-01-24 HU HU9902618A patent/HU226203B1/hu not_active IP Right Cessation
- 1997-01-24 PL PL97328069A patent/PL186473B1/pl not_active IP Right Cessation
- 1997-01-24 AU AU13168/97A patent/AU717755B2/en not_active Ceased
- 1997-01-24 KR KR10-1998-0705747A patent/KR100495690B1/ko not_active IP Right Cessation
- 1997-01-24 CZ CZ19982335A patent/CZ292899B6/cs not_active IP Right Cessation
- 1997-01-24 NZ NZ325912A patent/NZ325912A/xx not_active IP Right Cessation
- 1997-01-24 TR TR1998/01443T patent/TR199801443T2/xx unknown
- 1997-12-27 ZA ZA9700669A patent/ZA97669B/xx unknown
-
1998
- 1998-07-16 NO NO19983300A patent/NO321329B1/no not_active IP Right Cessation
- 1998-07-20 IS IS4799A patent/IS4799A/is unknown
- 1998-08-20 BG BG102710A patent/BG102710A/xx unknown
-
2000
- 2000-12-14 US US09/735,487 patent/US6528251B2/en not_active Expired - Fee Related
-
2003
- 2003-01-15 US US10/342,188 patent/US20030152917A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO321329B1 (no) | Fremgangsmate til a fastsette kjemoterapi for pasienter som er HIV positive, basert pa fenotypisk legemiddelfolsomhet hos pasientens HIV-stammer | |
| US20070134766A1 (en) | Methods of assessing hiv integrase inhibitor therapy | |
| Ambrose et al. | In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques | |
| Wapling et al. | Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer | |
| WO2006038908A2 (en) | Ancestral and cot viral sequences, proteins and immunogenic compositions | |
| Chopera et al. | Immune-mediated attenuation of HIV-1 | |
| Jármy et al. | Phenotypic analysis of the sensitivity of HIV‐1 to inhibitors of the reverse transcriptase, protease, and integrase using a self‐inactivating virus vector system | |
| EP1285971B1 (de) | Verfahren zur phänotypischen und genotypischen Bestimmung der Arzneimittelsensitivität von HIV Intergase-Varianten | |
| Salminen et al. | Construction and biological characterization of infectious molecular clones of HIV-1 subtypes B and E (CRF01_AE) generated by the polymerase chain reaction | |
| CA2244735C (en) | Method of managing the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains | |
| RU2174014C2 (ru) | Способ определения оптимальной химиотерапии пациентов, серопозитивных по вич, основанный на фенотипической лекарственной чувствительности человеческих штаммов вич | |
| Yang et al. | Human immunodeficiency virus type 2 capsid protein mutagenesis defines the determinants for Gag–Gag interactions | |
| CA2760781A1 (en) | Hiv-1-c resistance monitoring | |
| WO2007118849A2 (en) | Methods and means for assessing hiv gag/protease inhibitor therapy | |
| McMichael et al. | Host genetics and viral diversity: report from a global HIV vaccine enterprise working group | |
| Pankrac | Development and Evaluation of a Heterogenous Virus-Like Particle (VLP) Formulation to Achieve HIV-1 Latency Reversal and Cure | |
| JP2002159297A (ja) | プロテアーゼ活性の測定方法 | |
| Ferrantelli et al. | Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience | |
| WO2015179793A1 (en) | Vectors and compositions for stable expression of antigens in mycobacteria | |
| JP2007515386A (ja) | Ｈｉｖ感染個体の治療用免疫化 | |
| Paolucci et al. | HIV-1 plasma variants encoding truncated reverse transcriptase (RT) in a patient with high RT-specific CD8+ memory T-cell response | |
| RU98116294A (ru) | Способ определения оптимальной химиотерапии пациентов, серопозитивных по вич, основанный на фенотипической лекарственной чувствительности человеческих штаммов вич | |
| Mulinge | " Impact of polymorphisms in the HIV Envelope on tropism determination and on infectivity of primary CD4+ T cells and macrophages | |
| KR20190104586A (ko) | 예비-면역화 단계가 없는 hiv 면역요법 | |
| Kelly et al. | Forced selection of tRNAGlu reveals the importance of two adenosine-rich RNA loops within the U5-PBS for SIVsmmPBj replication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |